Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 269

1.

Geraniol attenuates α-synuclein expression and neuromuscular impairment through increase dopamine content in MPTP intoxicated mice by dose dependent manner.

Rekha KR, Selvakumar GP, Santha K, Inmozhi Sivakamasundari R.

Biochem Biophys Res Commun. 2013 Nov 1;440(4):664-70. doi: 10.1016/j.bbrc.2013.09.122. Epub 2013 Oct 5.

PMID:
24103762
2.

Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.

Sathiya S, Ranju V, Kalaivani P, Priya RJ, Sumathy H, Sunil AG, Babu CS.

Neuropharmacology. 2013 Oct;73:98-110. doi: 10.1016/j.neuropharm.2013.05.025. Epub 2013 Jun 6.

PMID:
23747572
3.

Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.

Gibrat C, Saint-Pierre M, Bousquet M, Lévesque D, Rouillard C, Cicchetti F.

J Neurochem. 2009 Jun;109(5):1469-82. doi: 10.1111/j.1471-4159.2009.06072.x. Epub 2009 Mar 28.

4.

GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.

Hadjiconstantinou M, Mariani AP, Neff NH.

Brain Res. 1989 Apr 10;484(1-2):297-303.

PMID:
2565752
5.

MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons.

Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ.

Neuroreport. 2000 Jan 17;11(1):211-3.

PMID:
10683860
6.

Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.

Shimoji M, Zhang L, Mandir AS, Dawson VL, Dawson TM.

Brain Res Mol Brain Res. 2005 Mar 24;134(1):103-8.

PMID:
15790534
7.

Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK.

Neurobiol Dis. 2012 Mar;45(3):1051-67. doi: 10.1016/j.nbd.2011.12.024. Epub 2011 Dec 14.

PMID:
22198503
8.

Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration.

Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL.

Neurotoxicology. 2004 Sep;25(5):761-9.

PMID:
15288507
9.

Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.

Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S.

J Neurochem. 2000 Feb;74(2):721-9.

10.

Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.

Schlüter OM, Fornai F, Alessandrí MG, Takamori S, Geppert M, Jahn R, Südhof TC.

Neuroscience. 2003;118(4):985-1002.

PMID:
12732244
11.

Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.

Perfeito R, Cunha-Oliveira T, Rego AC.

Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3. Review.

PMID:
23743292
12.

Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.

Song LK, Ma KL, Yuan YH, Mu Z, Song XY, Niu F, Han N, Chen NH.

PLoS One. 2015 Jun 26;10(6):e0131281. doi: 10.1371/journal.pone.0131281. eCollection 2015.

13.

A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.

Yano R, Yokoyama H, Kuroiwa H, Kato H, Araki T.

J Mol Neurosci. 2009 Sep;39(1-2):211-9. doi: 10.1007/s12031-009-9181-z. Epub 2009 Feb 7. Erratum in: J Mol Neurosci. 2009 Sep;39(1-2):320.

PMID:
19199078
14.

Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice.

Liu K, Shi N, Sun Y, Zhang T, Sun X.

Neurochem Res. 2013 Jan;38(1):201-7. doi: 10.1007/s11064-012-0909-8. Epub 2012 Nov 2.

PMID:
23117422
15.

Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.

Grünblatt E, Mandel S, Maor G, Youdim MB.

J Neurochem. 2001 Apr;77(1):146-56.

16.

Selective alterations of gene expression in mice induced by MPTP.

Xu Z, Cawthon D, McCastlain KA, Slikker W Jr, Ali SF.

Synapse. 2005 Jan;55(1):45-51.

PMID:
15499605
17.

Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.

Pérez-H J, Carrillo-S C, García E, Ruiz-Mar G, Pérez-Tamayo R, Chavarría A.

Toxicology. 2014 May 7;319:38-43. doi: 10.1016/j.tox.2014.02.009. Epub 2014 Mar 4.

PMID:
24607817
18.

Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.

Rai SN, Yadav SK, Singh D, Singh SP.

J Chem Neuroanat. 2016 Jan;71:41-9. doi: 10.1016/j.jchemneu.2015.12.002. Epub 2015 Dec 12.

PMID:
26686287
19.

Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice.

Vivacqua G, Biagioni F, Yu S, Casini A, Bucci D, D'Este L, Fornai F.

J Chem Neuroanat. 2012 Jul;44(2):76-85. doi: 10.1016/j.jchemneu.2012.04.003. Epub 2012 May 8.

PMID:
22580273
20.

Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo.

Zhang HN, An CN, Zhang HN, Pu XP.

Neurosci Lett. 2010 Apr 26;474(2):99-103. doi: 10.1016/j.neulet.2010.03.016. Epub 2010 Mar 19.

PMID:
20227465

Supplemental Content

Support Center